###begin article-title 0
###xml 109 114 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Kaposi's sarcoma associated herpes virus-encoded viral FLICE inhibitory protein activates transcription from HIV-1 Long Terminal Repeat via the classical NF-kappaB pathway and functionally cooperates with Tat
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 56 61 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 115 120 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 290 295 <span type="species:ncbi:9606">Human</span>
###xml 433 438 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The nuclear transcription factor NF-kappaB binds to the HIV-1 long terminal repeat (LTR) and is a key regulator of HIV-1 gene expression in cells latently infected with this virus. In this report, we have analyzed the ability of Kaposi's sarcoma associate herpes virus (KSHV, also known as Human Herpes virus 8)-encoded viral FLIP (Fas-associated death domain-like IL-1 beta-converting enzyme inhibitory protein) K13 to activate the HIV-1 LTR.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 45 50 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 160 165 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 456 461 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 500 505 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 655 660 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 707 712 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 756 761 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 801 806 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
We present evidence that vFLIP K13 activates HIV-1 LTR via the activation of the classical NF-kappaB pathway involving c-Rel, p65 and p50 subunits. K13-induced HIV-1 LTR transcriptional activation requires the cooperative interaction of all three components of the IKK complex and can be effectively blocked by inhibitors of the classical NF-kappaB pathway. K13 mutants that lacked the ability to activate the NF-kappaB pathway also failed to activate the HIV-1 LTR. K13 could effectively activate a HIV-1 LTR reporter construct lacking the Tat binding site but failed to activate a construct lacking the NF-kappaB binding sites. However, coexpression of HIV-1 Tat with K13 led to synergistic activation of HIV-1 LTR. Finally, K13 differentially activated HIV-1 LTRs derived from different strains of HIV-1, which correlated with their responsiveness to NF-kappaB pathway.
###end p 5
###begin title 6
Conclusions
###end title 6
###begin p 7
###xml 57 61 <span type="species:ncbi:37296?0.6348314606741573">HHV8</span>
###xml 76 81 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 158 163 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Our results suggest that concomitant infection with KSHV/HHV8 may stimulate HIV-1 LTR via vFLIP K13-induced classical NF-kappaB pathway which cooperates with HIV-1 Tat protein.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 121 122 121 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 382 383 382 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 384 385 384 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 596 597 596 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 598 599 598 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 794 795 794 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 978 979 974 975 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 1306 1307 1298 1299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 1500 1501 1484 1485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 1502 1503 1486 1487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 4 39 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 41 46 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 154 159 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 348 353 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 392 397 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 653 658 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 821 826 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 948 953 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1161 1166 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1382 1385 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1390 1395 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The human immunodeficiency virus type 1 (HIV-1) establishes latent infection following integration into the host genome [1]. The expression of integrated HIV-1 provirus in cells latently infected with this virus is controlled at the level of transcription by an interplay between distinct cellular and viral transcription factors which bind to the HIV-1 long terminal repeat (LTR) [1-4]. The HIV-1 LTR is divided into three regions: U3, R and U5, which contain four functional elements: transactivation response element (TAR), a basal or core promoter, a core enhancer, and a modulatory element [1,4]. The viral transactivator Tat is a key activator of HIV-1 LTR via its binding to the TAR region, while the core region contains three binding sites for Sp1 transcription factor and a TATA box [1]. The enhancer region of HIV-1 LTR contains two highly conserved consecutive copies of kappaB elements at nucleotides -104 to -81 that are critical for HIV-1 replication in T cells [1]. Finally, the modulatory region harbors binding sites for numerous transcription factors, such as c-Myb, NF-AT, USF and AP1. Among the various signaling pathways known to activate HIV-1 LTR, the NF-kappaB pathway is particularly important as it is activated by several cytokines involved in immune and inflammatory response [1]. However, all pathways that stimulate NF-kappaB do not reactivate latent HIV and HIV-1 gene expression is also known to be regulated by NF-kappaB-independent mechanisms, for example via Tat [2,3].
###end p 9
###begin p 10
###xml 157 158 145 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 159 160 147 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 431 432 403 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 433 434 405 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 809 810 750 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 961 962 898 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1139 1140 1068 1069 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1512 1513 1425 1426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1699 1700 1604 1605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1701 1703 1606 1608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
There are five known members of the NF-kappaB family in mammalian cells including p50/p105 (NF-kappaB1), p52/p100 (NF-kappaB2), p65 (RelA), c-Rel, and RelB [5,6]. Although many dimeric forms of NF-kappaB have been described, the classical NF-kappaB complex is a heterodimer of the p65/RelA and p50 subunits. The activity of NF-kappaB is tightly regulated by their association with a family of inhibitory proteins, called IkappaBs [5-7]. The best characterized Rel-IkappaB interaction is between IkappaBalpha and p65-p50 dimer, which blocks the ability of NF-kappaB to enter the nucleus. Stimulation by a number of stimuli results in the activation of a multi-subunit IkappaB kinase (IKK) complex, which contains two catalytic subunits, IKK1/IKKalpha and IKK2/IKKbeta, and a regulatory subunit, NEMO/IKKgamma [7]. The IKK complex leads to the inducible phosphorylation of IkappaB proteins at two conserved serine residues located within their N-terminal region [5]. Phosphorylation of IkappaB proteins lead to their ubiquitination and subsequent proteasome-mediated degradation, thereby releasing NF-kappaB from their inhibitory influence [7]. Once released, NF-kappaB is free to migrate to the nucleus and bind to the promoter of specific genes possessing its cognate binding site. In addition to the above classical NF-kappaB pathway, an alternative (or noncanonical) pathway of NF-kappaB activation that involves proteasome-mediated processing of p100/NF-kappaB2 into p52 subunit, has been described recently [8]. Unlike the classical NF-kappaB pathway, which involves IKK2 and NEMO, activation of the alternative NF-kappaB pathway by TNF family receptors is critically dependent on NIK and IKK1 [9,10].
###end p 10
###begin p 11
###xml 186 188 182 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 189 191 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 467 469 463 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 470 472 466 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 562 564 558 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 721 723 717 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 724 726 720 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 727 729 723 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 63 68 <span type="species:ncbi:9606">Human</span>
###xml 85 89 <span type="species:ncbi:37296?0.6348314606741573">HHV8</span>
###xml 176 184 <span type="species:ncbi:9606">patients</span>
Kaposi's sarcoma associated herpes virus (KSHV), also known as Human herpes virus 8 (HHV8), is a gamma-2 herpes virus which is frequently associated with malignancy among AIDS patients [11-13]. In addition to Kaposi's sarcoma (KS), KSHV genome has been consistently found in primary effusion lymphoma (PEL) or body cavity lymphoma and multicentric Castleman's disease. KSHV genome is known to encode for homologs of several cytokines, chemokines and their receptors [11-13]. However, none of the above proteins is expressed in cells latently-infected with KSHV [11]. KSHV also encodes for a protein called K13 (or orf71), which is one of the few viral proteins known to be expressed in cells latently infected with KSHV [11,14-16].
###end p 11
###begin p 12
###xml 233 235 233 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 411 413 411 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 414 416 414 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 539 541 539 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 542 544 542 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 344 371 <span type="species:ncbi:10279">molluscum contagiosum virus</span>
###xml 388 394 <span type="species:ncbi:9796">equine</span>
The K13 protein contains two homologous copies of a Death Effector Domain (DED) that is also present in the prodomains of caspase 8 (also known as FLICE), caspase 10 and cellular FLICE Inhibitory Protein (cFLIP, also known as MRIT) [17]. Proteins with two DEDs have been discovered in other viruses as well, including MC159L and MC160 from the molluscum contagiosum virus and E8 from the equine herpes virus 2 [18-20]. These virally encoded DED-containing proteins are collectively referred to as vFLIPs (viral FLICE Inhibitory Proteins) [18-20].
###end p 12
###begin p 13
###xml 143 145 139 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 146 148 142 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 360 362 352 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 363 365 355 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 527 530 519 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs </italic>
###xml 211 216 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 470 475 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 614 619 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
We recently demonstrated that KSHV vFLIP K13 possesses the unique ability to activate both the classical and the alternate NF-kappaB pathways [21-24]. Several recent studies suggest that binding of NF-kappaB to HIV-1 LTR may not be sufficient and interaction with additional viral and cellular factors may be required to induce its transcriptional activation [25,26]. As such, in this report we have carried out a detailed analysis of the ability of K13 to activate the HIV-1 LTR and analyzed the contribution of the canonical vs alternate NF-kappaB signaling pathways, various subunits of the IKK complex and the HIV-1 Tat to this process.
###end p 13
###begin title 14
Results
###end title 14
###begin title 15
###xml 24 29 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
vFLIP K13 activates the HIV-1 LTR
###end title 15
###begin p 16
###xml 221 225 221 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A&#8211;C</xref>
###xml 647 649 640 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C</xref>
###xml 1164 1166 1143 1145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1D</xref>
###xml 75 80 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 193 198 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 351 356 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 406 412 <span type="species:ncbi:9796">equine</span>
###xml 448 453 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 564 569 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 702 707 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1015 1020 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1097 1102 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1140 1145 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1215 1220 <span type="species:ncbi:9606">human</span>
###xml 1285 1290 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
We used a luciferase reporter construct to test the effect of vFLIP K13 on HIV-1 LTR transcriptional activation. This reporter construct expresses the firefly luciferase gene downstream of the HIV-1 LTR. As shown in Fig. 1A-C transient transfection of vFLIP K13 in 293T and Cos7 cells led to significant (3 and 5 fold, respectively) activation of the HIV-1 LTR where as expression of the vFLIP E8 from the equine herpes virus 2 failed to do so. As HIV-1 LTR is known to be responsive to proinflammatory cytokines, we also carried out a comparative analysis of the HIV-1 LTR activation by K13, TNF-alpha and IL-1beta in 293T cells. As shown in Fig 1C, while K13-induced approximately 3-fold increase in HIV-1 LTR transcriptional activation, treatment with TNF-alpha(50 ng/ml) and IL-1beta (50 ng/ml) resulted in 5-6 fold increase. A possible explanation for this difference lies in the fact that unlike TNF-alpha and IL-1beta, K13 lacks the ability to induce the transcription factor AP1, which is known to activate HIV-1 LTR. We also tested whether vFLIP K13 possesses the ability to activate the HIV-1 LTR in cells naturally infected with HIV-1. As shown in Fig. 1D, transient transfection of K13 in Jurkat cells (human T cell lymphoma cell line) led to modest (2-fold) activation of HIV-1 LTR transcription activity.
###end p 16
###begin title 17
###xml 63 68 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
K13 mutants defective in NF-kappaB activation fail to activate HIV-1 LTR
###end title 17
###begin p 18
###xml 123 125 119 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 632 634 616 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 676 678 660 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 829 831 809 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 1011 1013 991 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 189 194 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 330 335 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 977 982 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1120 1125 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
We have recently generated point mutants of the vFLIP K13 which differ in their ability to activate the NF-kappaB pathway [27]. In order to test the hypothesis that vFLIP K13 activates the HIV-1 LTR via NF-kappaB pathway, we carried out a comparative analysis of the ability of wild-type and mutant K13 constructs to activate the HIV-1 LTR reporter construct. In a parallel experiment, we also tested the effect of different K13 constructs on an NF-kappaB luciferase reporter construct to serve as a positive control. The luciferase expression in the latter construct is driven by four copies of a consensus NF-kappaB binding-site [28]. Consistent with our published results [27], the triple mutant 58AAA demonstrated a complete lack of NF-kappaB reporter activation while the mutant 67AAA retained partial ability to do so (Fig 2A). Importantly, essentially a similar pattern of reporter activation was obtained when the wild-type and mutant K13 constructs were tested on the HIV-1 LTR reporter construct (Fig 2B). Collectively, the above results suggested the involvement of the NF-kappaB pathway in vFLIP K13-induced HIV-1 LTR activation.
###end p 18
###begin title 19
###xml 63 68 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
vFLIP K13 induces binding of specific transcription factors to HIV-1 LTR
###end title 19
###begin p 20
###xml 255 257 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 577 579 569 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 826 828 818 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 57 62 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 171 176 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 447 452 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 474 479 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 708 713 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
In order to test the hypothesis that vFLIP K13 activates HIV-1 LTR by inducing the binding of specific transcription factors to the NF-kappaB binding sites present in the HIV-1 LTR, we used an electrophoretic mobility shift assay (EMSA). As shown in Fig. 3A, nuclear extracts from Jurkat cells expressing vFLIP K13 demonstrated significant DNA-binding activity on radiolabelled oligonucleotides-derived from the NF-kappaB binding sites present in HIV-1 LTR. In contrast, no HIV-1 LTR DNA-binding activity was observed in nuclear extracts of empty vector-expressing cells (Fig. 3A, compare lanes 1 and 2). The specificity of the complex was demonstrated by its disappearance upon competition with excess cold HIV-1 LTR oligonucleotide duplex and lack of effect upon competition with a non-specific oligonucleotide duplex (Fig. 3A, lanes 3 and 4).
###end p 20
###begin title 21
###xml 77 82 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Nature and subunit composition of K13-induced transcription factors bound to HIV-1 LTR
###end title 21
###begin p 22
###xml 218 219 206 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 373 375 357 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 434 437 418 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs </italic>
###xml 847 849 823 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 486 491 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 591 596 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 738 743 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1011 1016 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
In addition to the classical NF-kappaB pathway, an alternative (or non-canonical) pathway of NF-kappaB activation, which involves proteasome-mediated processing of p100/NF-kappaB2 into p52 subunit, has been described [8]. We have recently demonstrated that vFLIP K13 can activate the alternate NF-kappaB pathway via an IKK1-dependent and NIK- and IKK2-independent process [24]. In order to determine the contribution of the classical vs alternate NF-kappaB pathway to vFLIP K13-induced HIV-1 LTR activation, we used a supershift assay to analyze the nature of the protein complexes bound to HIV-1 LTR from nuclear extracts of vFLIP K13-expressing cells. This assay demonstrated that p50 and c-Rel subunits are the major components of the HIV-1 LTR-bound NF-kappaB complexes induced by vFLIP K13 with modest contribution from the p65 subunit (Fig. 3B). As the p50, c-Rel and p65 subunits are primarily activated by the classical NF-kappaB pathway, the above results support the hypothesis that K13 activates the HIV-1 LTR via the classical NF-kappaB pathway.
###end p 22
###begin title 23
###xml 54 59 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Role of classical NF-kappaB activation in K13-induced HIV-1 LTR reporter activity
###end title 23
###begin p 24
###xml 203 205 191 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 393 395 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 347 352 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 593 598 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
We have previously demonstrated that vFLIP K13 activates the classical NF-kappaB pathway via phosphorylation of IkappaBalpha, which leads to its ubiquitination and subsequent degradation via proteasome [22]. We used a phosphorylation-resistant mutant of IkappaBalpha to test the involvement of the classical NF-kappaB pathway in vFLIP K13-induced HIV-1 LTR reporter activity. As shown in Fig. 4A, a phosphorylation-resistant mutant of IkappaBalpha (IkappaBalphaSS32/36AA), in which the two critical N-terminal serine residues have been mutated to alanine, completely blocked vFLIP K13-induced HIV-1 LTR reporter activity.
###end p 24
###begin p 25
###xml 184 186 180 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 325 327 321 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 452 454 448 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4C</xref>
###xml 606 608 602 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4C</xref>
###xml 879 883 871 875 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B&#8211;C</xref>
###xml 145 150 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 425 430 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 530 535 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 965 970 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1047 1052 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1223 1228 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
We used siRNA-mediated downregulation of key subunits of the classical and alternate NF-kappaB pathways to test their involvement in K13-induced HIV-1 LTR activation. As shown in Fig. 4B, we achieved effective silencing of c-Rel and RelA/p65 expression by siRNA-mediated silencing. Consistent with our supershift assay (Fig. 3B), siRNA-mediated silencing of c-Rel expression led to almost complete suppression of K13-induced HIV-1 LTR activation (Fig. 4C). Similarly, silencing of p65 expression led to significant suppression of HIV-1 LTR activity, although some residual activity was still evident (Fig. 4C). Although p100 acts as a precursor of p52, another important function of p100 is to retain the RelB/p50 and RelB/p52 complexes in the cytoplasm. As such, in order to shut-off the alternate NF-kappaB pathway, we chose to silence the expression of RelB. As shown in Fig. 4B-C, siRNA-mediated downregulation of RelB, had no significant effect on K13-induced HIV-1 LTR activity. We also failed to observe any effect of p100/p52 silencing on HIV-1 LTR activation (data not shown). Taken together, the above results demonstrate a key role of the c-Rel and p65 subunits of the classical NF-kappaB pathway in K13-induced HIV-1 LTR reporter activation.
###end p 25
###begin title 26
###xml 62 67 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Role of individual subunits of the IKK complex in K13-induced HIV-1 LTR activation
###end title 26
###begin p 27
###xml 182 184 171 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 413 415 402 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
###xml 282 287 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 319 324 <span type="species:ncbi:10090">mouse</span>
###xml 441 446 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 551 556 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 640 645 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 845 850 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
K13 is known to associate with a 700 kDa multi-subunit IKK complex, which consists of two catalytic subunits, IKK1/IKKalpha and IKK2/IKKbeta and a regulatory subunit, NEMO/IKKgamma [22]. We tested the involvement of the individual components of the IKK complex in vFLIP K13-induced HIV-1 LTR reporter activity by using mouse fibroblast (MEF) cells deficient in IKK1, IKK2 and NEMO, respectively. As shown in Fig. 5A, we observed significant HIV-1 LTR reporter activity by the expression of vFLIP K13 in the wild type MEF cells. In contrast, almost no HIV-1 LTR reporter activity was observed in NEMO-deficient cells. However, some residual HIV-1 LTR reporter activity was observed in IKK1- and IKK2-deficient MEF cells. Collectively, the above results suggest that synergistic action of IKK1, IKK2 and NEMO is required for maximal activation of HIV-1 LTR by K13.
###end p 27
###begin p 28
###xml 389 391 373 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 411 413 395 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5B</xref>
###xml 127 132 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 433 438 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 634 639 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Next we sought to determine whether pharmacological inhibitors of the NF-kappaB pathway may be used to block vFLIP K13-induced HIV-1 LTR reporter activation. Lactacystin and MG132 are inhibitors of proteasome and block the NF-kappaB pathway by preventing the degradation of IkappaB. On the other hand, arsenic acid is believed to block the NF-kappaB pathway by inhibiting the IKK complex [29]. As shown in Fig. 5B, vFLIP K13-induced HIV-1 LTR reporter activation was effectively blocked by MG132, lactacystin and arsenic acid. These results suggest that inhibitors of the NF-kappaB pathway might have a role in preventing K13-induced HIV-1 LTR reporter activation.
###end p 28
###begin title 29
###xml 31 36 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Effect of Murr1 on K13-induced HIV-1 LTR activation
###end title 29
###begin p 30
###xml 82 84 82 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 85 87 85 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 255 257 255 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 446 448 438 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 643 645 635 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5C</xref>
###xml 989 991 981 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 209 214 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 285 290 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 310 315 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 544 549 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 602 607 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 710 715 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 789 794 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 892 897 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Murr1 is a gene product that has been previously implicated in copper regulation [30,31]. A recent study demonstrated that Murr1 is highly expressed in CD4+ T cells and serve as a genetic inhibitor factor for HIV-1 replication in the resting lymphocytes [32]. Murr1 was shown to block HIV-1 LTR activation and HIV-1 replication by inhibiting the proteasomal degradation of IkappaB and blocking basal and cytokine-stimulated NF-kappaB activation [32]. Based on the above study demonstrating the importance of Murr1 as an endogenous regulator of HIV-1 LTR activation, we tested its effect on K13-induced HIV-1 LTR activation. As shown in Figure 5C, co-expression of Murr1 led to significant block in K13-induced HIV-1 LTR reporter activity, thereby suggesting that K13-induced activation of HIV-1 replication in resting lymphoid cells may be regulated by Murr1 and K13 may selectively activate HIV-1 replication in activated cells in which expression of Murr1 is known to be down-regulated [32].
###end p 30
###begin title 31
###xml 26 31 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 53 56 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Synergistic activation of HIV-1 LTR by vFLIP K13 and HIV Tat protein
###end title 31
###begin p 32
###xml 121 122 121 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 123 124 123 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 383 384 383 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 478 479 478 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 644 646 644 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6A</xref>
###xml 651 653 651 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6B</xref>
###xml 767 769 767 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 994 996 990 992 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6C</xref>
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 69 74 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 259 264 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 387 392 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 429 432 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 518 523 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 718 723 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 924 929 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1050 1055 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Tat is a viral nuclear protein that plays an essential role in HIV-1 gene expression at the transcriptional level [2,3]. Tat has been shown to associate with p300/CBP and P/CAF histone acetyltransferases (HAT) and efficient activation of the integrated HIV-1 LTR is largely dependent on Tat-dependent rearrangement of the nucleosome positioned at the transcription start site [2]. HIV-1 LTR is known to bind and respond to HIV Tat protein via a specific Tat-binding site [2]. We used deletion mutagenesis of the HIV-1 LTR to test whether vFLIP induced transcriptional activation is dependent on this Tat-binding site. As shown in Figures 6A and 6B, a bulge mutant (containing deletion of nucleotides +23/+25) of HIV-1 LTR, which is defective in Tat activation [33], had no significant effect on vFLIP K13-induced reporter activity. In contrast, vFLIP K13 failed to activate a luciferase report construct containing an HIV-1 LTR in which the NF-kappaB binding sites had been mutated (Fig. 6C). The above results confirm that vFLIP activates the HIV-1 LTR via the NF-kappaB binding sites and can do so independent of the Tat-binding site.
###end p 32
###begin p 33
###xml 241 243 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 244 246 240 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 247 249 243 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 456 457 444 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 458 460 446 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 461 463 449 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 852 854 836 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6D</xref>
###xml 966 968 950 952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6E</xref>
###xml 193 198 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 366 371 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 445 450 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 603 608 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 811 816 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 925 930 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1060 1065 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1142 1147 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1248 1253 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1371 1376 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Transcriptional activation of genes is usually regulated by multiple transcription factors acting in concert. Thus, while NF-kappaB has been shown to play a major role in the activation of the HIV-1 LTR, it fails to do so when acting alone [25,34-36]. Along the same lines, the transactivating function of Tat protein requires the presence of NF-kappaB sites in the HIV-1 LTR and Tat protein is known to cooperate with NF-kappaB to activate the HIV-1 LTR [1,34,36]. We hypothesized that a functional interaction between K13-induced NF-kappaB and Tat may be particularly important in the early stages of HIV-1 infection when the amount of Tat is limited. To test this hypothesis, we began by performing a dose-response analysis of Tat and selected a dose of Tat (20 ng/ml) which led to sub-maximal activation of HIV-1 LTR activation in 293T cells (Fig. 6D). Next, we analyzed the effect of co-expression of Tat on K13-induced HIV-1 LTR activation. As shown in Figure 6E, while transfection of K13 (250-500 ng/well) led to approximately 2.5-3.5 fold increase in HIV-1 LTR activation, transfection of Tat (20 ng/well) induced 4-fold increase in HIV-1 LTR activity. However, co-expression of K13 with Tat led to a synergistic 12-fold activation of the HIV-1 LTR. These results suggest that K13-induced NF-kappaB functions synergistically with the Tat protein to activate the HIV-1 LTR.
###end p 33
###begin title 34
###xml 62 65 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Effect of vFLIP K13 on LTRs-Derived from different strains of HIV
###end title 34
###begin p 35
###xml 175 177 175 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 382 384 378 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 385 387 381 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 503 505 499 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 506 508 502 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 670 672 658 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 673 675 661 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 880 882 868 870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 883 885 871 873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 1048 1050 1036 1038 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7A</xref>
###xml 1217 1219 1205 1207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7A</xref>
###xml 1517 1521 1497 1501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7A,B</xref>
###xml 51 56 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 409 414 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 534 539 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 828 831 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 961 966 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1205 1210 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1330 1335 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1474 1479 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1663 1668 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
There is considerable sequence diversity among the HIV-1 isolates that comprise the current global pandemic and these can be grouped into several distinct subtypes or clades [37]. In particular, the LTRs of different subtypes show distinct enhancer-promoter configuration and vary in the sequence and number of binding sites for different transcription factor, including NF-kappaB [38,39]. Although different HIV-1 LTRs are transcriptionally active, they differ in the level of basal reporter activity [38,39]. In addition, different HIV-1 LTRs are known to show differential response to TNF-alpha treatment, which correlates with the number of NF-kappaB binding sites [38,39]. Therefore, we sought to determine whether vFLIP K13 will differentially activate luciferase reporter constructs driven by LTRs derived from different HIV strains. Consistent with the published studies [38,39], we observed considerable difference in the basal activities of different HIV-1 LTRs promoters when transfected into 293T cells along with an empty vector (Fig. 7A). More importantly, coexpression of vFLIP K13 led to differential activation of luciferase reporter constructs containing LTRs from different subtypes of HIV-1 (Fig. 7A). Thus, subtype C, which possesses three NF-kappaB binding sites showed the maximum increase in vFLIP-induced HIV-1 LTR reporter activity while subtype E, which possesses only one NF-kappaB binding site showed the lowest level of basal and vFLIP-induced HIV-1 LTR transcriptional activation (Fig. 7A,B). These results demonstrate that, similar to situation with TNFalpha, K13 may differentially activate LTRs derived from different strains of HIV-1, which correlate with their NF-kappaB binding sites.
###end p 35
###begin title 36
Discussion
###end title 36
###begin p 37
###xml 399 401 399 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 402 404 402 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 457 459 457 459 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 519 521 519 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 522 524 522 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 569 574 569 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 705 713 705 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 714 716 714 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 719 724 719 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink">First</italic>
###xml 834 836 834 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 837 839 837 839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 842 848 842 848 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Second</italic>
###xml 855 861 855 861 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al </italic>
###xml 1015 1017 1015 1017 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 1020 1025 1020 1025 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Third</italic>
###xml 1166 1168 1166 1168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 1216 1224 1216 1224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 1341 1349 1341 1349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 1612 1614 1612 1614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 37 42 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 150 154 <span type="species:ncbi:37296?0.6348314606741573">HHV8</span>
###xml 159 164 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 275 279 <span type="species:ncbi:37296?0.6348314606741573">HHV8</span>
###xml 444 449 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 667 671 <span type="species:ncbi:37296?0.6348314606741573">HHV8</span>
###xml 676 681 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 731 735 <span type="species:ncbi:37296?0.6348314606741573">HHV8</span>
###xml 740 745 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1000 1003 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1027 1031 <span type="species:ncbi:37296?0.6348314606741573">HHV8</span>
###xml 1068 1073 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1147 1152 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1193 1197 <span type="species:ncbi:37296?0.6348314606741573">HHV8</span>
###xml 1287 1291 <span type="species:ncbi:37296?0.6348314606741573">HHV8</span>
###xml 1296 1301 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1511 1516 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1544 1548 <span type="species:ncbi:37296?0.6348314606741573">HHV8</span>
###xml 1593 1598 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Although co-infection with HHV-8 and HIV-1 is known to synergistically increase the incidence of KS, until recently intracellular interaction between HHV8 and HIV-1 has not received adequate attention under the assumption that these viruses infect distinct cell types. Thus, HHV8 is typically believed to infect B lymphocytes, epithelial cells, keratinocytes, KS tumor cells, and endothelial cells [40,41], while the predominant host cells for HIV-1 are CD4+ T lymphocytes, dendritic cells, and mononuclear phagocytes [41,42]. However, as recently pointed out by Huang et al, several lines of evidence suggest that the above assumption may not be completely true and HHV8 and HIV-1 may, in fact, interact in vivo [41]. First, both HHV8 and HIV-1 can efficiently infect cells of monocyte/macrophage lineage, including dendritic cells [43,44]. Second, Moir et al have shown that induction of CD4 and CXCR4 on B cells by CD40 stimulation leads to an increased susceptibility of these cells to T-trophic HIV infection [45]. Third, HHV8-infected B cells can be infected by HIV-1 via a cell-cell pathway and such infected B cells can support productive HIV-1 replication [46]. Finally, the range of HHV8-susceptible cells in vivo is unclear at the present. Therefore, it stands to reason that HHV8 and HIV-1 genomes may co-exist in the same cells in vivo and reciprocally regulate the gene expression of each other. Support for the above hypothesis is provided by a recent study which demonstrated that co-culture of HIV-1-infected CD4+ T cells with HHV8-infected B cell lines resulted in increased HIV-1 replication [47].
###end p 37
###begin p 38
###xml 365 367 361 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 947 949 935 937 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 122 127 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 202 206 <span type="species:ncbi:37296?0.6348314606741573">HHV8</span>
###xml 216 221 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 290 294 <span type="species:ncbi:37296?0.6348314606741573">HHV8</span>
###xml 320 325 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 423 428 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 456 461 <span type="species:ncbi:9606">human</span>
###xml 725 730 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 794 799 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
With the goal of elucidating intracellular signaling interactions which could be potentially involved in the induction of HIV-1 replication by HHV-8, we carried out a detailed analysis of the effect of HHV8 vFLIP on HIV-1 LTR activation. Consistent with an earlier report, we observed that HHV8 vFLIP strongly activates HIV-1 LTR in an NF-kappaB-dependent fashion [48]. We further demonstrate that vFLIP K13 could activate HIV-1 LTR in both epithelial and human lymphoma cell lines, although the magnitude of stimulatory effect was more pronounced in the epithelial cells. A possible explanation for this difference may lie in the differential expression of proteins that could modulate the effect of K13 on NF-kappaB and/or HIV-1 LTR activation. As an example, we demonstrate that K13-induced HIV-1 LTR activation can be effectively blocked by Murr1, a recently identified inhibitor of the NF-kappaB pathway which is highly expressed in T cells [32]. However, alternative explanation, including difference in the transfection efficiency between different cell lines, could apply as well.
###end p 38
###begin p 39
###xml 345 350 341 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">First</italic>
###xml 499 505 491 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Second</italic>
###xml 691 696 683 688 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Third</italic>
###xml 853 860 833 840 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Finally</italic>
###xml 213 218 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 294 299 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 601 606 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 710 715 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 961 966 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
We have recently reported that vFLIP K13 can activate both the classical and alternate NF-kappaB pathways and, as such, we were interested in determining the relative contribution of these pathways to K13-induced HIV-1 LTR activation. Based on the following data, we believe that activation of HIV-1 LTR is mainly through the classical pathway. First, our gel super-shift assay demonstrated that NF-kappaB complexes formed by vFLIP expression were primarily composed of c-Rel, p50 and p65 subunits. Second, siRNA-mediated downregulation of c-Rel and p65 led to near complete inhibition of K13-induced HIV-1 LTR activation whereas silencing of RelB expression was without significant effect. Third, K13-induced HIV-1 LTR activation was completely inhibited by super-repressor form of IkappaBalpha, which primarily blocks the classical NF-kappaB pathway. Finally, while K13 activates the alternate NF-kappaB pathway independent of IKK2, it failed to activate the HIV-1 LTR in IKK2-deficient MEFs.
###end p 39
###begin p 40
###xml 147 149 143 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 150 152 146 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 533 538 525 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink">First</italic>
###xml 687 689 675 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 875 881 859 865 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Second</italic>
###xml 1057 1059 1037 1039 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 1060 1062 1040 1042 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 258 263 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 485 490 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 709 714 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1130 1135 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1308 1313 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Based on some early gene-knockout studies, IKK1 was believed to be not involved in cytokine-induced activation of the classical NF-kappaB pathway [49-51]. In the present study, we have observed that, in addition to IKK2- and NEMO-deficient MEFs, K13-induced HIV-1 LTR activation was markedly reduced in IKK1-deficient MEFs as well. We believe that the above results with IKK1-deficient cells do not necessarily support the involvement of the alternate NF-kappaB pathway in K13-induced HIV-1 LTR activation for the following reasons. First, we have recently reported that K13-induced p65/50 DNA binding and NF-kappaB transcriptional activation is markedly reduced in IKK1-deficient MEFs [23] Thus, the reduced HIV-1 LTR activation in the IKK1-deficient cells observed in the current study is consistent with requirement for IKK1 in K13-induced classical NF-kappaB activation. Second, recent studies suggest that IKK1 may be involved in transcriptional activation of classical NF-kappaB responsive genes through its ability to phosphorylate histones and p65 [52-54]. Thus, taken together, our results demonstrate that K13 activates HIV-1 LTR through the activation of the classical NF-kappaB pathway, in which IKK1 plays a major role. Thus, selective inhibitors of IKK1 may have a role in blocking K13-induced HIV-1 LTR transcriptional activation. However, it is important to point out that while IKK1 may be uniquely important for K13-induced classical NF-kappaB activation pathway, maximal activation of this pathway via K13 relies on cooperative interaction between IKK1, IKK2 and NEMO.
###end p 40
###begin p 41
###xml 422 423 418 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 616 617 604 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 618 620 606 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 732 733 716 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 734 736 718 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 737 739 721 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 740 742 724 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 1069 1071 1049 1051 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 1072 1074 1052 1054 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 203 208 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 292 297 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 502 507 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 721 726 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 835 840 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 939 944 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 950 955 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1141 1146 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1217 1222 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1320 1325 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1471 1476 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1516 1521 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The transcription of cellular and viral genes is regulated by structural and functional interactions among a number of transcriptional factors that act in concert. This is also known to be the case with HIV-1 LTR. Thus, while NF-kappaB plays a major role in the transcriptional activation of HIV-1, it requires synergistic interaction with a number of cellular and viral proteins for maximal stimulation of this activity [1]. Although NF-kappaB is known to interact with Sp1, Ets and NF-AT to activate HIV-1 LTR, cooperative interaction between NF-kappaB and Tat has received the most interaction in the literature [1,55]. Tat has been shown to act synergistically with PMA, PHA and Tax-induced NF-kappaB to activate the HIV-1 LTR [1,34,36,55]. Consistent with these previous studies, we demonstrate that although K13 can activate the HIV-1 LTR by itself, it functionally cooperates with Tat to synergistically activate transcription from HIV-1 LTR. HIV-1 infection itself is known to induce persistent NF-kappaB activation, which is probably mediated via Tat and Nef [56,57], and interacts in a positive-feedback manner with Tat to enhance HIV-1 replication. However, in the immediate post-integration period of the HIV-1 life-cycle, Tat is expressed at very low levels which may not be enough to effectively stimulate HIV-1 LTR activation. Therefore, it is conceivable that vFLIP K13 could amplify the activity of Tat via NF-kappaB activation and thus support enhanced HIV-1 replication during the early stages of HIV-1 infection or in cells which express Tat at suboptimal levels.
###end p 41
###begin p 42
###xml 168 170 168 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 306 308 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 462 464 458 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 641 643 633 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 828 830 812 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 4 32 <span type="species:ncbi:12721">human immunodeficiency virus</span>
###xml 361 366 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 923 928 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1041 1046 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1261 1265 <span type="species:ncbi:37296?0.6348314606741573">HHV8</span>
###xml 1344 1349 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The human immunodeficiency virus has considerably diversified during its worldwide spread in the current pandemic and can be classified into several distinct subtypes [37]. Subtype B is predominant in North America and Europe, subtype E in Southeast Asia and subtype C in sub-Saharan Africa, respectively [58]. Previous studies have demonstrated that LTRs from HIV-1 subtypes B, C and E vary in number and binding sites for NF-kappaB in their enhancer elements [59]. Thus, subtype C isolates are known to contain three functional NF-kappaB binding sites, as compared to two such sites in the enhancer of the more commonly studied subtype B [59]. On the other hand, in the subtype E, one of the NF-kappaB-binding sites has been switched to a GABP site, resulting only one functional NF-kappaB site and gain of a new specificity [60]. Consistent with the above results, in the present study we demonstrate that vFLIP-induced HIV-1 LTR activation is strongest in subtype C and weakest in subtype E. Thus, the differential response of different HIV-1 LTRs to K13-induced transcriptional activation may be explained on the basis of number of functional NF-kappaB sites in their enhancer elements. Future studies should address the question whether co-infection with HHV8 has a differential effect on the replication and natural history of different HIV-1 subtypes.
###end p 42
###begin title 43
Methods
###end title 43
###begin title 44
Plasmids, cell lines and reagents
###end title 44
###begin p 45
###xml 113 115 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 595 597 595 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 788 790 781 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
###xml 791 793 784 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 872 874 861 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
###xml 1501 1503 1489 1491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 380 385 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 564 569 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 629 632 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 707 712 <span type="species:ncbi:10090">mouse</span>
###xml 1347 1351 <span type="species:ncbi:37296?0.6348314606741573">HHV8</span>
Plasmids containing pcDNA3-K13-Flag and pcDNA3-E8-Flag, pRSV/LacZ and 293T cells have been described previously [21]. An expression construct encoding Murr-1 was generated by RT-PCR using cDNA prepared from H460 cells as a template and subsequently cloned in pcDNA3 vector with a C-terminal HA tag. Luciferase reporter constructs containing LTRs derived from different strains of HIV-1 (pBlue3'LTR-Luc-A-F) were obtained from AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH from Drs. Reink Jeeninga and Ben Berkhout. Wild-type and mutant HIV-1 LTR reporter constructs [61] and expression constructs for HIV Tat were obtained from Dr. Richard Gaynor. The IKKalpha-/- and IKKbeta-/- mouse embryonic fibroblast cells were generated in Dr. Inder Verma's laboratory [62,63] and IKKgamma/NEMO-/- cells were generated in Dr. Michael Karin's laboratory [64]. These cells were kindly provided by Dr. Richard Gaynor and were maintained in DMEM supplemented with 10% FBS. Jurkat cells were cultured in RPMI medium supplemented with 10% FBS and selected in the presence of 1500 mug/ml of G418 (Invitrogen). 293T cells were grown in DMEM with 10% FBS. Arsenic Acid was purchased from Sigma. MG132 and lactacystin were purchased from Calbiochem and Biomol, respectively. Retrovirus constructs containing C-terminal Flag epitope tagged HHV8 vFLIP (K13-Flag) was generated in MSCV neo-based retroviral vector and amphotropic viruses generated and used for infection as described previously [22].
###end p 45
###begin title 46
Electrophoretic mobility shift assay
###end title 46
###begin p 47
###xml 88 90 88 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 390 392 386 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 103 106 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Electrophoretic mobility shift assay was performed essentially as described previously [22], except an HIV LTR oligonucleotide duplex (sense strand, 5' TGC TAC AAG GGA CTT TCC GCT GGG GAC TTT CCA GG 3') was used instead of kappaB binding oligonucleotide. Nuclear extracts were prepared from Jurkat cells stably expressing an empty vector or vFLIP K13, which have been described previously [23]. Antibodies against p50, p65, RelB and c-Rel were purchased from Santa Cruz Biotechnology. An antibody against p52 was purchased from Upstate biotechnology
###end p 47
###begin title 48
Luciferase reporter assay
###end title 48
###begin p 49
###xml 300 302 297 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 106 109 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 687 690 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
293 T cells were transfected in duplicate in a 24-well plate with the various test plasmids along with an HIV LTR/luciferase reporter construction (10 ng/well) and a pRSV/LacZ (beta-galactosidase) reporter construct (75 ng/well) using calcium phosphate transfection protocol as described previously [21]. Cells were lysed 36-48 hours later and extracts were used for the measurement of firefly luciferase and galactosidase activity. Luciferase activity was normalized relative to the galactosidase activity to control for the difference in the transfection efficiency. Cos-7, Jurkat and MEF cells were transiently transfected with empty vector (pCDNA3) or K13 (500 ng/well) along with a HIV/luciferase reporter construct (100 ng/well) and a synthetic Renilla luciferase (phRL-TK; Promega) reporter vector (75 ng/well) by using LIPOFECTAMINE 2000 Reagent (Invitrogen, Carlsbad, CA) according to manufacturer's instruction. Thirty-six hours after transfection, cells lysates used for reporter assays. Luciferase activity was normalized relative to the Renilla luciferase activity to control for the difference in the transfection efficiency. The values shown are averages (Mean +/- S.E.) of one representative experiment out of three in which each transfection was performed in duplicate.
###end p 49
###begin title 50
siRNA Oligonucleotides
###end title 50
###begin p 51
###xml 567 569 567 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B65">65</xref>
siRNA oligonucleotides with two thymidine residues (dTdT) at the 3'-end of the sequence were designed to p65 (sense, 5'-GCCCUAUCCCUUUACGUCAdTdT-3'), c-Rel (sense, 5'-CAACCGUGCUCCAAAUACU dTdT-3'), RelB (sense, AGAUCAUCGACGAGUACAUdTdT-3') and control (sense, 5' GCGCGCUUUGUAGGAUUCGdTdT-3'), along with their corresponding antisense oligonucleotides. The RNA oligonucleotides were synthesized at RNA Oligonucleotide Synthesis Core facility, UT Southwestern Medical center. siRNA oligonucleotides (80 nM) were transfected using calcium phosphate as described previously [65].
###end p 51
###begin title 52
Western Blot
###end title 52
###begin p 53
###xml 73 75 73 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 148 154 <span type="species:ncbi:9986">rabbit</span>
###xml 204 209 <span type="species:ncbi:10090">mouse</span>
Western blot analysis was performed essentially as described previously [22]. Primary antibodies used in these experiments were: p65, c-Rel, Rel-B (rabbit polyclonal, Santa Cruz biotechnology) and actin (mouse monoclonal, Sigma).
###end p 53
###begin title 54
List of Abbreviations Used
###end title 54
###begin p 55
###xml 173 177 <span type="species:ncbi:37296?0.6348314606741573">HHV8</span>
###xml 179 184 <span type="species:ncbi:9606">Human</span>
###xml 201 206 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 208 238 <span type="species:ncbi:11676">human immunodeficiency virus 1</span>
###xml 371 377 <span type="species:ncbi:10090">murine</span>
DED, death effector domain; EMSA, electrophoretic mobility shift assay; FLICE, Fas-associated death domain-like IL-1 beta-converting enzyme; FLIP, FLICE inhibitory protein; HHV8, Human herpes virus 8; HIV-1, human immunodeficiency virus 1; KS, Kaposi's sarcoma; NEMO, NF-kappaB essential modulator; NIK, NF-kappaB-inducing kinase; NF-kappaB, Nuclear factor kappa B; MEF, murine embryonic fibroblast; PEL, primary effusion lymphoma, TNFR, Tumor necrosis factor receptor; IkappaB, inhibitor of NF-kappaB, IKK, IkappaB kinase; vFLIP, viral FLICE inhibitory protein; LTR, long terminal repeat.
###end p 55
###begin title 56
Competing Interests
###end title 56
###begin p 57
The author(s) declare that they have no competing interests.
###end p 57
###begin title 58
Authors' contributions
###end title 58
###begin p 59
QS and HM carried out most of the experiments described in this manuscript. PMC conceived of the study and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.
###end p 59
###begin title 60
Acknowledgement
###end title 60
###begin p 61
We will like to thank Drs. Inder Verma, Michael Karin and Richard Gaynor for MEF cells and various expression and reporter plasmids. The following reagents were obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: pBlue3'LTR-Luc-A-F from Drs. Reink Jeeninga and Ben Berkhout. This work was supported by a grant from the National Institutes of Health (CA85177).
###end p 61
###begin article-title 62
###xml 14 19 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Regulation of HIV-1 gene transcription: from lymphocytes to microglial cells
###end article-title 62
###begin article-title 63
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 gene expression: lessons from provirus and non-integrated DNA
###end article-title 63
###begin article-title 64
###xml 31 36 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Multifaceted activities of the HIV-1 transactivator of transcription, Tat
###end article-title 64
###begin article-title 65
###xml 69 74 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A compilation of cellular transcription factor interactions with the HIV-1 LTR promoter
###end article-title 65
###begin article-title 66
NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses
###end article-title 66
###begin article-title 67
The NF-kappa B and I kappa B proteins: new discoveries and insights
###end article-title 67
###begin article-title 68
Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity
###end article-title 68
###begin article-title 69
Two pathways to NF-kappaB
###end article-title 69
###begin article-title 70
NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100
###end article-title 70
###begin article-title 71
Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway
###end article-title 71
###begin article-title 72
###xml 41 46 <span type="species:ncbi:9606">human</span>
Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8)
###end article-title 72
###begin article-title 73
Molecular biology and pathogenesis of Kaposi sarcoma-associated herpesvirus
###end article-title 73
###begin article-title 74
###xml 63 68 <span type="species:ncbi:9606">Human</span>
Molecular Genetics of Kaposi's Sarcoma-Associated Herpesvirus (Human Herpesvirus 8) Epidemiology and Pathogenesis
###end article-title 74
###begin article-title 75
###xml 33 52 <span type="species:ncbi:37296">human herpesvirus 8</span>
Expression of K13/v-FLIP gene of human herpesvirus 8 and apoptosis in Kaposi's sarcoma spindle cells
###end article-title 75
###begin article-title 76
###xml 100 119 <span type="species:ncbi:37296">human herpesvirus 8</span>
The 222- to 234-kilodalton latent nuclear protein (LNA) of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) is encoded by orf73 and is a component of the latency-associated nuclear antigen
###end article-title 76
###begin article-title 77
###xml 70 89 <span type="species:ncbi:37296">human herpesvirus 8</span>
Transcription mapping of the Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) genome in a body cavity-based lymphoma cell line (BC-1)
###end article-title 77
###begin article-title 78
The death effector domain protein family: regulators of cellular homeostasis
###end article-title 78
###begin article-title 79
Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors
###end article-title 79
###begin article-title 80
Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas- and TNFR1-induced apoptosis
###end article-title 80
###begin article-title 81
A novel family of viral death effector domain-containing molecules that inhibit both CD-95- and tumor necrosis factor receptor-1-induced apoptosis
###end article-title 81
###begin article-title 82
Modulation of the NF-kappa B pathway by virally encoded death effector domains-containing proteins
###end article-title 82
###begin article-title 83
###xml 4 9 <span type="species:ncbi:9606">Human</span>
The Human Herpes Virus 8-encoded Viral FLICE Inhibitory Protein Physically Associates with and Persistently Activates the Ikappa B Kinase Complex
###end article-title 83
###begin article-title 84
###xml 30 35 <span type="species:ncbi:9606">human</span>
Molecular genetic analysis of human herpes virus 8-encoded viral FLICE inhibitory protein-induced NF-kappaB activation
###end article-title 84
###begin article-title 85
###xml 48 53 <span type="species:ncbi:9606">human</span>
Activation of alternative NF-kappa B pathway by human herpes virus 8-encoded Fas-associated death domain-like IL-1 beta-converting enzyme inhibitory protein (vFLIP)
###end article-title 85
###begin article-title 86
###xml 24 29 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 62 67 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Binding of NF-kB to the HIV-1 LTR is not sufficient to induce HIV-1 LTR activity
###end article-title 86
###begin article-title 87
###xml 44 49 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 116 121 <span type="species:ncbi:9606">human</span>
An increase in p50/p65 NF-kB binding to the HIV-1 LTR is not sufficient to increase viral expression in the primary human astrocyte
###end article-title 87
###begin article-title 88
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human herpes virus 8-encoded viral FLICE-inhibitory protein induces cellular transformation via NF-kappaB activation
###end article-title 88
###begin article-title 89
Cross-linking CD40 on B cells rapidly activates nuclear factor-kappa B
###end article-title 89
###begin article-title 90
Arsenic inhibits NF-kappaB-mediated gene transcription by blocking IkappaB kinase activity and IkappaBalpha phosphorylation and degradation
###end article-title 90
###begin article-title 91
###xml 83 86 <span type="species:ncbi:9615">dog</span>
Identification of a new copper metabolism gene by positional cloning in a purebred dog population
###end article-title 91
###begin article-title 92
The ubiquitously expressed MURR1 protein is absent in canine copper toxicosis
###end article-title 92
###begin article-title 93
###xml 33 38 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The gene product Murr1 restricts HIV-1 replication in resting CD4+ lymphocytes
###end article-title 93
###begin article-title 94
###xml 45 73 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Specific binding of RNA polymerase II to the human immunodeficiency virus trans-activating region RNA is regulated by cellular cofactors and Tat
###end article-title 94
###begin article-title 95
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
###xml 65 99 <span type="species:ncbi:11908">human T-cell leukemia virus type 1</span>
Human immunodeficiency virus type 1 genome activation induced by human T-cell leukemia virus type 1 Tax protein is through cooperation of NF-kappaB and Tat
###end article-title 95
###begin article-title 96
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 production from infected peripheral blood T cells after HTLV-I induced mitogenic stimulation
###end article-title 96
###begin article-title 97
###xml 18 23 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Activation of the HIV-1 LTR by T cell mitogens and the trans-activator protein of HTLV-I
###end article-title 97
###begin article-title 98
###xml 17 22 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 27 32 <span type="species:ncbi:11709?0.8305084745762712">HIV-2</span>
Heterogeneity of HIV-1 and HIV-2
###end article-title 98
###begin article-title 99
###xml 85 120 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Functional differences between the long terminal repeat transcriptional promoters of human immunodeficiency virus type 1 subtypes A through G
###end article-title 99
###begin article-title 100
###xml 27 32 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Differential regulation of HIV-1 clade-specific B, C, and E long terminal repeats by NF-kappaB and the Tat transactivator
###end article-title 100
###begin article-title 101
###xml 12 31 <span type="species:ncbi:37296">human herpesvirus 8</span>
The role of human herpesvirus 8 in the pathogenesis of Kaposi's sarcoma
###end article-title 101
###begin article-title 102
###xml 42 61 <span type="species:ncbi:37296">human herpesvirus 8</span>
###xml 66 101 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Reciprocal regulatory interaction between human herpesvirus 8 and human immunodeficiency virus type 1
###end article-title 102
###begin article-title 103
###xml 61 66 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Cells of the monocyte-macrophage lineage and pathogenesis of HIV-1 infection
###end article-title 103
###begin article-title 104
###xml 103 111 <span type="species:ncbi:9606">patients</span>
Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients
###end article-title 104
###begin article-title 105
###xml 67 86 <span type="species:ncbi:37296">human herpesvirus 8</span>
Monocytes in Kaposi's sarcoma lesions are productively infected by human herpesvirus 8
###end article-title 105
###begin article-title 106
###xml 103 138 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
CD40-Mediated induction of CD4 and CXCR4 on B lymphocytes correlates with restricted susceptibility to human immunodeficiency virus type 1 infection: potential role of B lymphocytes as a viral reservoir
###end article-title 106
###begin article-title 107
###xml 0 28 <span type="species:ncbi:12721">Human immunodeficiency virus</span>
Human immunodeficiency virus replication in a primary effusion lymphoma cell line stimulates lytic-phase replication of Kaposi's sarcoma-associated herpesvirus
###end article-title 107
###begin article-title 108
###xml 13 43 <span type="species:ncbi:11676">human immunodeficiency virus 1</span>
###xml 59 78 <span type="species:ncbi:37296">human herpesvirus 8</span>
Induction of human immunodeficiency virus 1 replication by human herpesvirus 8
###end article-title 108
###begin article-title 109
###xml 0 19 <span type="species:ncbi:37296">Human herpesvirus 8</span>
Human herpesvirus 8 viral FLICE-inhibitory protein inhibits Fas-mediated apoptosis through binding and prevention of procaspase-8 maturation
###end article-title 109
###begin article-title 110
###xml 31 35 <span type="species:ncbi:10090">mice</span>
Limb and skin abnormalities in mice lacking IKKalpha
###end article-title 110
###begin article-title 111
###xml 52 56 <span type="species:ncbi:10090">mice</span>
Abnormal morphogenesis but intact IKK activation in mice lacking the IKKalpha subunit of IkappaB kinase [see comments]
###end article-title 111
###begin article-title 112
###xml 70 74 <span type="species:ncbi:10090">mice</span>
Complete lack of NF-kappaB activity in IKK1 and IKK2 double-deficient mice: additional defect in neurulation
###end article-title 112
###begin article-title 113
Histone H3 phosphorylation by IKK-alpha is critical for cytokine-induced gene expression
###end article-title 113
###begin article-title 114
A nucleosomal function for IkappaB kinase-alpha in NF-kappaB-dependent gene expression
###end article-title 114
###begin article-title 115
HTLV-I tax induction of biologically active NF-kappa B requires IKK1-mediated phosphorylation of RelA/p65
###end article-title 115
###begin article-title 116
###xml 58 86 <span type="species:ncbi:12721">human immunodeficiency virus</span>
An inducible transcription factor activates expression of human immunodeficiency virus in T cells
###end article-title 116
###begin article-title 117
###xml 67 102 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Activation of transcription factor NF-kappaB by the Tat protein of human immunodeficiency virus type 1
###end article-title 117
###begin article-title 118
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Nef leads to inhibition or activation of T cells depending on its intracellular localization
###end article-title 118
###begin article-title 119
###xml 24 29 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk
###end article-title 119
###begin article-title 120
###xml 65 100 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Dysregulation through the NF-kappaB enhancer and TATA box of the human immunodeficiency virus type 1 subtype E promoter
###end article-title 120
###begin article-title 121
###xml 17 52 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Evolution of the human immunodeficiency virus type 1 long terminal repeat promoter by conversion of an NF-kappaB enhancer element into a GABP binding site
###end article-title 121
###begin article-title 122
IkappaB kinase alpha (IKKalpha) regulation of IKKbeta kinase activity
###end article-title 122
###begin article-title 123
###xml 15 19 <span type="species:ncbi:10090">mice</span>
IKK1-deficient mice exhibit abnormal development of skin and skeleton
###end article-title 123
###begin article-title 124
###xml 29 33 <span type="species:ncbi:10090">mice</span>
Severe liver degeneration in mice lacking the IkappaB kinase 2 gene
###end article-title 124
###begin article-title 125
###xml 7 11 <span type="species:ncbi:10090">mice</span>
###xml 95 100 <span type="species:ncbi:9606">human</span>
Female mice heterozygous for IKK gamma/NEMO deficiencies develop a dermatopathy similar to the human X-linked disorder incontinentia pigmenti
###end article-title 125
###begin article-title 126
Induction of apoptosis by X-linked ectodermal dysplasia receptor via a caspase 8-dependent mechanism
###end article-title 126
###begin title 127
Figures and Tables
###end title 127
###begin p 128
###xml 0 32 0 32 <bold xmlns:xlink="http://www.w3.org/1999/xlink">K13 activates HIV-1 LTR promoter</bold>
###xml 14 19 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 142 147 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 520 525 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1062 1067 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1291 1296 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
K13 activates HIV-1 LTR promoter. A. 293T cells were transfected with an empty vector or the indicated constructs (100 ng/well) along with an HIV-1 LTR/luciferase reporter construct (10 ng/well) and a pRSV/LacZ (beta-galactosidase) reporter construct (75 ng/well), and the experiment was performed as described under "Materials and Methods." The values shown are averages (Mean +/- S.E.) of one representative experiment out of three in which each transfection was performed in duplicate. B. A dose-response analysis of HIV-1 LTR activation by K13 and pro-inflammatory cytokines. 293T cells were transfected with the indicated amounts of a K13 expression plasmid and luciferase assay performed 36 h post-transfection as described for (A). The total amount of transfected DNA was kept constant by adding an empty vector. For experiments involving TNF-alpha and IL-1beta, cells were treated with the indicated concentration of cytokines 12 h after transfection of the reporter plasmids and assayed for reporter activity after 24 h of stimulation. C. K13 activates HIV-1 LTR in Cos-7 cells. The experiment was performed as described in 1A except LIPOFECTAMINE 2000 Reagent (Invitrogen, Carlsbad, CA) was used for transfection and Renilla luciferase was used for normalization. D. K13 activates HIV-1 LTR in Jurkat cells. The experiment was performed as described for 1C by using LIPOFECTAMINE 2000 Reagent (Invitrogen, Carlsbad, CA).
###end p 128
###begin p 129
###xml 0 101 0 97 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Activation of HIV- LTR by K13 mutants correlates with their ability to activate the NF-&#954;B pathway</bold>
###xml 14 17 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 612 617 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Activation of HIV- LTR by K13 mutants correlates with their ability to activate the NF-kappaB pathway. A. NF-kappaB activation by mutants of K13. 293T cells were transfected with an empty vector (pCDNA3) or the indicated K13 expression constructs (100 ng/well) along with an NF-kappaB/luciferase reporter construct (75 ng/well) and an pRSV/LacZ (beta-galactosidase) reporter construct (75 ng/well) and luciferase reporter assay performed as described in Fig. 1A. The values shown are averages (mean +/- SEM) of one representative experiment out of three in which each transfection was performed in duplicate. B. HIV-1 LTR activation by wild-type and mutant K13 constructs. The experiment was performed as described for Fig. 1A.
###end p 129
###begin p 130
###xml 0 36 0 36 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Electrophoretic mobility shift assay</bold>
###xml 190 195 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 315 320 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 492 497 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 554 560 <span type="species:ncbi:9986">rabbit</span>
###xml 588 593 <span type="species:ncbi:10090">mouse</span>
###xml 774 779 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Electrophoretic mobility shift assay. A. The nuclear extract from Jurkat cells stably expressing an empty vector (lane 1) and K13 (lanes 2-4) were used for EMSA. The position of the induced HIV-1 LTR complex is marked with an asterisk. The specificity of the complex is demonstrated by competition with excess cold HIV-1 LTR probe (lane 3) and a nonspecific (N.S.) probe (lane 4), respectively. B. A supershift assay showing the subunit composition of K13-induced NF-kappaB subunits bound to HIV-1 LTR. The supershift assay was performed using a control rabbit antisera (lane 3), control mouse antisera (lane 4), or antisera against p50 (lane 5), p65 (lane 6), p52 (lane 7), Rel B (lane 8) and c-Rel (lane 9) subunits of NF-kappaB, respectively. The position of the induced HIV-1 LTR complex is marked with an asterisk, while the super-shifted bands are marked by arrowheads.
###end p 130
###begin p 131
###xml 0 61 0 57 <bold xmlns:xlink="http://www.w3.org/1999/xlink">K13 activates HIV LTR through the classical NF-&#954;B pathway</bold>
###xml 14 17 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 136 139 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
K13 activates HIV LTR through the classical NF-kappaB pathway. A. 293T cells were transfected with an empty vector or K13 along with an HIV LTR/luciferase reporter construct and a beta-galactosidase reporter construct as described in Fig. 1A. The amount of IkappaBalphaSS32/36AA inhibitor plasmid (500 ng/well) was five times the amount of vector (pcDNA3) or K13 (100 ng/well) plasmid. The values shown are averages (Mean +/- S.E.) of one representative experiment out of three in which each transfection was performed in duplicate. B. Western blot analysis showing siRNA-mediated knock-down of p65, c-Rel and RelB expression. The blot was re-probed with a monoclonal antibody against actin (bottom panel) to show equal loading of all lanes and specificity of gene silencing. C. 293T cells were transfected with an empty vector or a K13 expression plasmid along with a control siRNA oligo-duplexes or siRNA duplexes against c-Rel, p65 and RelB, respectively. The luciferase reporter assay was performed as described in Fig 1A.
###end p 131
###begin p 132
###xml 0 45 0 45 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Mechanism of K13-induced HIV-1 LTR activation</bold>
###xml 25 30 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 85 90 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 252 255 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 918 921 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1007 1010 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1427 1432 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1528 1531 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Mechanism of K13-induced HIV-1 LTR activation. A. Role of IKK complex in K13-induced HIV-1 LTR reporter activity. Wild-type and IKK-deficient cells were transiently transfected with an empty vector or K13 expression plasmid (500 ng/well) along with an HIV/luciferase reporter construct (100 ng/well) and a synthetic Renilla luciferase (phRL-TK) reporter vector (75 ng/well) by using LIPOFECTAMINE 2000 Reagent (Invitrogen, Carlsbad, CA) according to manufacturer's instruction. Thirty-six hours after transfection, cell lysates were used for reporter assays. Luciferase activity was normalized relative to the Renilla luciferase activity to control for the difference in the transfection efficiency. The values shown are averages (Mean +/- S.E.) of one representative experiment out of three in which each transfection was performed in duplicate. B. Inhibitors of the NF-kappaB pathway significantly block K13-actived HIV LTR promoter. 293T cells were transfected with the empty vector or K13 along with an HIV LTR/luciferase reporter construct and a beta-galactosidase reporter construct as described in Fig.1A. Eight hours after transfection, cells were treated with DMSO or different inhibitors for 24 h and then lysed for the reporter assay. The values shown are averages (Mean +/- S.E.) of one representative experiment out of three in which each transfection was performed in duplicate. C. Effect of Murr1 on K13-induced HIV-1 LTR activation. 293T cells were transfected with an empty vector (pCDNA3) or K13 along with an HIV LTR/luciferase reporter construct and a beta-galactosidase reporter construct as described in Fig. 1A. The amount of Murr1 plasmid (500ng/well) was five times the amount of vector or K13 (100ng/well). The values shown are averages (Mean +/- S.E.) of one representative experiment out of three in which each transfection was performed in duplicate.
###end p 132
###begin p 133
###xml 0 61 0 61 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effect of HIV Tat protein on K13-induced HIV-1 LTR activation</bold>
###xml 10 13 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 41 46 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 154 157 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 401 406 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 424 429 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 506 511 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 603 608 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 665 670 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Effect of HIV Tat protein on K13-induced HIV-1 LTR activation. A-C. 293T cells were transfected with an empty vector (pCDNA3) or K13 along with different HIV LTR/luciferase reporter constructs and beta-galactosidase as described in Fig. 1A. The values shown are averages (Mean +/- S.E.) of one representative experiment out of three in which each transfection was performed in duplicate. A, Wild type HIV-1 LTR reporter; B, HIV-1 LTR reporter with deletion of Tat-binding site (nucleotides +23 to +25); C. HIV-1 LTR reporter lacking the NF-kappaB binding-sites. D. Dose-response analysis of Tat-induced HIV-1 LTR activation. E. K13 and Tat synergistically activate HIV-1 LTR. The experiment was performed as described for Fig. 6 A. The total amount of transfected DNA was kept constant by adding empty vector.
###end p 133
###begin p 134
###xml 0 52 0 52 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Differential activation of HIV-1 subtype LTRs by K13</bold>
###xml 27 32 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 218 221 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 469 474 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Differential activation of HIV-1 subtype LTRs by K13. A. 293T cells were transfected with an empty vector (pCDNA3) or K13 along with luciferase reporter constructs containing LTRs derived from the indicated strains of HIV and a beta-galactosidase reporter construct as described in Fig. 1A. The values shown are averages (Mean +/- S.E.) of one representative experiment out of three in which each transfection was performed in duplicate. B. Partial sequence of LTRs of HIV-1 subtypes A through F. The LTR region spanning positions -129 to -77 of subtype A is shown at the top. The NF-kappaB binding motifs are shaded gray.
###end p 134

